Executive Interviews
Australia’s 60,000 Business Succession Crisis: Why Good Companies Will Close Their Doors
The Australian Business Growth Fund identified approximately 162,000 privately held businesses in Australia with revenue between AUD$2 million and AUD$100 million. More than two-thirds are owned by people of retirement age. When surveyed, another two-thirds do not have a succession plan in place. The mathematics are stark. 60,000 businesses owned by someone of retirement age […]
The ‘Banknote’ Blueprint: Halocell’s Plan to Print the Next Solar Revolution
Beyond rooftops—Halocell Energy’s “banknote” printing creates highly efficient, flexible, lightweight, recyclable and cost-effective solar cells for shaded areas and from dawn to dusk, detailing the three-horizon plan.
The Iron Chaperone: Alterity’s High-Stakes Sprint on Brain Iron Redistribution
Multiple System Atrophy (MSA) is a devastating neurological disease with no known cure. Alterity Therapeutics is breaking the “black box” of MSA with ATH434, a first-in-class drug that targets toxic iron accumulation. After successful Phase 2 results, the company is now scaling for a pivotal Phase 3 trial, positioning itself as a frontrunner in a multi-billion dollar orphan drug market.
The ‘Unused Billion’: How Points4Purpose is Disrupting the Flatlining Loyalty Market
The loyalty industry is plagued by “sameness,” leaving billions in value dormant. Ivan Schwartz’s Points4Purpose is disrupting this flatlining market by turning rewards into a liquid currency for rent, bills, and over 1.8 million charities.
1,000km, sustainable, efficient , no onboard pilot: How ‘Gap Drone ’ is rewriting the rules of remote logistics
Can autonomous drones solve Australia’s “tyranny of distance”? GAP Drone CEO Liesl Haris thinks so. With the launch of ATLAS—an autonomous transport logistics aircraft system—the company is bypassing traditional infrastructure to deliver 50kg payloads over 1,000km. Dubbed the “Uber of airfreight,” GAP Drone is tackling the “too hard basket” of remote logistics, partnering with Australia Post to provide First Nations communities and regional hubs with reliable, low-cost access to medicine, food, and economic opportunity. By operating within current regulatory frameworks and utilising a “no-runway” launch model, GAP Drone is transforming air freight from an expensive luxury into a scalable utility.
Precision Care, Zero Clicks: Why the Future of the NDIS is Voice-First
Carelogix is solving the healthcare burnout crisis by replacing manual typing with a sophisticated AI “care co-pilot.” By reclaiming nearly half of a caregiver’s day, the platform offers a significant value inflection point for providers and investors in the trillion-dollar care economy.
Arterial Alchemy: Turning the ‘Ticking Time Bomb’ of Heart Disease into Excretable Waste
Current heart medications thin the “grease” in our blood, but Atherid Therapeutics is building the first biological clearing agent to actually scrub the pipes clean. With human trials slated for 2027, the goal is to make heart attacks a preventable and reversible condition.
Breaking the ‘Bird’s Nest’: How Amplia Therapeutics is Piercing the Shield of Pancreatic Cancer
Led by award-winning drug developer Dr. Chris Burns, Amplia Therapeutics (ASX: ATX) is taking a “one-two punch” approach to one of medicine’s deadliest challenges. By utilizing their lead asset, narmafotinib, to dismantle the protective “bird’s nest” of fibrotic tissue surrounding pancreatic tumors, Amplia has achieved a 35% interim response rate in Phase 2a trials. With FDA Fast Track status and critical survival data expected in 2026, the company is rapidly approaching a major commercial and clinical rerate.
The Better Pill to Swallow: Solving the $60B Drug Delivery Problem with AI
While most biotechs hunt for new molecules, BCS2 is fixing the ones we already have. Founder Stuart Gunzburg explains how his AI-powered platform transforms “insoluble” blockbuster drugs into rapid-acting sprays and films, creating a de-risked, high-speed pathway to market for a $60 billion opportunity.
Backed By Leading Investment Groups and Family Offices
